Enlivex Therapeutics (NASDAQ: ENLV) CEO details roadmap after positive Phase IIa Allocetra results

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. furnished a report describing a new communication to shareholders. The company’s Chief Executive Officer sent a letter outlining Enlivex’s strategic roadmap following positive Phase IIa Allocetra™ results. This shareholder letter, dated September 11, 2025, is attached as Exhibit 99.1 to the report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

On September 11, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), issued a letter from its Chief Executive Officer to shareholders outlining Enlivex’s strategic roadmap following positive Phase IIa Allocetra™ results. A copy of such letter is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

Exhibit No.
99.1		Letter issued by Enlivex Therapeutics Ltd. on September 11, 2025.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:	Oren Hershkovitz
	Title:	Chief Executive Officer

Date: September 11, 2025

2

FAQ

What did Enlivex Therapeutics Ltd. (ENLV) file in this Form 6-K?

Enlivex filed a Form 6-K to furnish a shareholder letter from its Chief Executive Officer. The letter outlines the company’s strategic roadmap following positive Phase IIa Allocetra™ results and is attached as Exhibit 99.1 to the report.

What is the main focus of Enlivex Therapeutics Ltd.’s September 2025 shareholder letter?

The shareholder letter focuses on Enlivex’s strategic roadmap after positive Phase IIa Allocetra™ results. It is intended to update shareholders on the company’s direction and is furnished as Exhibit 99.1 to the Form 6-K filed in September 2025.

How are the positive Phase IIa Allocetra results referenced by Enlivex Therapeutics Ltd. (ENLV)?

The report states that Enlivex’s strategic roadmap was outlined following positive Phase IIa Allocetra™ results. These results serve as the context for the CEO’s shareholder letter, which is incorporated into the Form 6-K as Exhibit 99.1 for investors to review.

Where can investors find the Enlivex Therapeutics Ltd. CEO’s shareholder letter?

Investors can find the CEO’s shareholder letter as Exhibit 99.1 to Enlivex’s Form 6-K. The report specifies that the letter, dated September 11, 2025, is furnished as an exhibit and incorporated by reference for shareholders and other interested readers.

Who signed the Enlivex Therapeutics Ltd. (ENLV) Form 6-K related to the shareholder letter?

The Form 6-K was signed on behalf of Enlivex Therapeutics Ltd. by Chief Executive Officer Oren Hershkovitz. His signature confirms the company’s authorization of the filing that furnishes the shareholder letter as Exhibit 99.1 on September 11, 2025.